Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allergan Falls as Supreme Court Dismisses Restasis Litigation

by Zacks Equity Research

Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

Acorda to Gain From Inbrija Sales and Neurological Pipeline

by Zacks Equity Research

Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.

Mylan (MYL) Up 8.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)

by Zacks Equity Research

Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Glaxo Presents Encouraging Data on Endometrial Cancer Drug

by Zacks Equity Research

Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.

Insys Plunges on Auditor's Concern About Insufficient Funds

by Zacks Equity Research

Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

Implied Volatility Surging for Mylan (MYL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Mylan (MYL) stock based on the movements in the options market lately.

    Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates

    by Zacks Equity Research

    Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.

    Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down

    by Zacks Equity Research

    Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.

    Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat

    by Zacks Equity Research

    Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.

    Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

    by Zacks Equity Research

    Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.

    Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.

    Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

    by Zacks Equity Research

    Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.

    Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

    Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

    by Zacks Equity Research

    Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

    Mylan's Generic Version of Advair Diskus Wins FDA Approval

    by Zacks Equity Research

    Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.

    J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study

    by Zacks Equity Research

    Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.

    Mylan (MYL) Jumps: Stock Rises 7.1%

    by Zacks Equity Research

    Mylan (MYL) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

    Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid

    by Zacks Equity Research

    Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.

    Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results

    by Zacks Equity Research

    Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.

    Can Allergan (AGN) Keep the Earnings Streak Alive in Q4?

    by Zacks Equity Research

    While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

    The Zacks Analyst Blog Highlights: Mylan, Altice USA and Keysight Technologies

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Mylan, Altice USA and Keysight Technologies

    John Blank headshot

    Davos Goes Live! Global Week Ahead

    by John Blank

    The 2019 theme is "Globalization 4.0: Shaping a Global Architecture in the Age of the Fourth Industrial Revolution."

    Tirthankar Chakraborty headshot

    New Strong Buy Stocks for January 21st

    by Tirthankar Chakraborty

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

    Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

    by Zacks Equity Research

    Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C